Platelet membrane-coated nanoparticle-mediated targeting delivery of Rapamycin blocks atherosclerotic plaque development and stabilizes plaque in apolipoprotein E-deficient (ApoE−/−) mice

• Published in: Nanomedicine Vol. 15; no. 1; pp. 13 - 24
• Main Authors: Song, Yanan, Huang, Zheyong, Liu, Xin, Pang, Zhiqing, Chen, Jing, Yang, Hongbo, Zhang, Ning, Cao, Zhonglian, Liu, Ming, Cao, Jiatian, Li, Chenguang, Yang, Xiangdong, Gong, Hui, Qian, Juying, Ge, Junbo
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.01.2019
• Subjects: Animals; Apolipoproteins E - genetics; Apolipoproteins E - physiology; Atherosclerosis; Atherosclerosis - drug therapy; Atherosclerosis - genetics; Atherosclerosis - pathology; Autophagy; Blood Platelets - physiology; Cell Membrane - chemistry; Cell Membrane - metabolism; Cells, Cultured; Drug Delivery Systems; Immunosuppressive Agents - pharmacology; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Nanoparticles - administration & dosage; Nanoparticles - chemistry; Plaque, Atherosclerotic - drug therapy; Plaque, Atherosclerotic - genetics; Plaque, Atherosclerotic - pathology; Platelet Adhesiveness; Platelet membrane-coated nanoparticle; Rapamycin; Sirolimus - pharmacology; Targeting delivery; RAP; vWF; PT; ALT; DLS; Targeting delivery; SMCs; Autophagy; HDL; Platelet membrane-coated nanoparticle; PNP; LDL; CM-NP; Atherosclerosis; BUN; ApoE−/− mice; RAP-PNP; AST; RAP-NP; Rapamycin; TC; APTT; PLGA; TG; TEM; DiD; HUVECs

Although certain success has been achieved in atherosclerosis treatment, tremendous challenges remain in developing more efficient strategies to treat atherosclerosis. Platelets have inherent affinity to plaques and naturally home to atherosclerotic sites. Rapamycin features potent anti-atherosclero...